Phaseline

Targets › UNC13A

UNC13A (Protein unc-13 homolog A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Sep 2027.

Plays a role in vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway. Involved in neurotransmitter release by acting in synaptic vesicle priming prior to vesicle fusion and participates in the activity-dependent refilling of readily releasable vesicle pool (RRP). (UniProt, Q9UPW8)

Open in Phaseline: the race on UNC13A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Trace NeuroscienceTRCN-1023
UNC13A function restoration therapy
UNC13APhase 1Amyotrophic Lateral SclerosisSep 2027

Conditions

Amyotrophic Lateral Sclerosis (1)

Modalities

small molecule (1)

Companies

Trace Neuroscience (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.